Format

Send to

Choose Destination
J Biol Chem. 2017 Jun 9;292(23):9745-9759. doi: 10.1074/jbc.M117.782433. Epub 2017 Apr 27.

Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies.

Author information

1
From the Department of Antibody Engineering, Biologics Research, Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland and.
2
the Department of Drug Metabolism and Pharmacokinetics, Glenmark Pharmaceuticals Limited, Glenmark Research Centre, Plot No. A-607, T.T.C. Industrial Area, MIDC, Mahape, Navi Mumbai 400 709, India.
3
From the Department of Antibody Engineering, Biologics Research, Glenmark Pharmaceuticals S.A., Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland and stanislas.blein@glenmarkpharma.com.

Abstract

Bispecific antibodies (bsAbs) are of significant importance to the development of novel antibody-based therapies, and heavy chain (Hc) heterodimers represent a major class of bispecific drug candidates. Current technologies for the generation of Hc heterodimers are suboptimal and often suffer from contamination by homodimers posing purification challenges. Here, we introduce a new technology based on biomimicry wherein the protein-protein interfaces of two different immunoglobulin (Ig) constant domain pairs are exchanged in part or fully to design new heterodimeric domains. The method can be applied across Igs to design Fc heterodimers and bsAbs. We investigated interfaces from human IgA CH3, IgD CH3, IgG1 CH3, IgM CH4, T-cell receptor (TCR) α/β, and TCR γ/δ constant domain pairs, and we found that they successfully drive human IgG1 CH3 or IgM CH4 heterodimerization to levels similar to or above those of reference methods. A comprehensive interface exchange between the TCR α/β constant domain pair and the IgG1 CH3 homodimer was evidenced by X-ray crystallography and used to engineer examples of bsAbs for cancer therapy. Parental antibody pairs were rapidly reformatted into scalable bsAbs that were free of homodimer traces by combining interface exchange, asymmetric Protein A binding, and the scFv × Fab format. In summary, we successfully built several new CH3- or CH4-based heterodimers that may prove useful for designing new bsAb-based therapeutics, and we anticipate that our approach could be broadly implemented across the Ig constant domain family. To our knowledge, CH4-based heterodimers have not been previously reported.

KEYWORDS:

CH3; T-cell receptor (TCR); antibody; antibody engineering; bispecific; exchange; heterodimer; interface; monoclonal antibody; protein engineering

PMID:
28450393
PMCID:
PMC5465497
DOI:
10.1074/jbc.M117.782433
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center